{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Engraftment failure is defined as the failure to achieve neutrophil engraftment by day 21; defined from day 0, day of autologous hematopoietic cell transplantation (AHCT), as the first of three consecutive days on which the patient's absolute neutrophil count is greater than 0.5x10(9)/l following the nadir. Transplant related mortality is defined as any subject who dies in the first 100 days post-AHCT of any non-relapse related cause.","groups":[{"description":"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)\n\n•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:\n\nCohort 1: add CFZ 20 mg/m\\^2 intravenous (IV) on days +1, +2\n\nCohort 2 : add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9\n\nCohort 3: add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m\\^2 IV given on days 42-43 then CFZ 56 mg/m\\^2 IV given on days 49-50, 56-57, then on days 70.","id":"OG000","title":"Cohort 1- CFZ 20 mg/m^2 (Day 1,2)"},{"description":"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)\n\n•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:\n\nCohort 1: add CFZ 20 mg/m\\^2 intravenous (IV) on days +1, +2\n\nCohort 2 : add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9\n\nCohort 3: add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m\\^2 IV given on days 42-43 then CFZ 56 mg/m\\^2 IV given on days 49-50, 56-57, then on days 70.","id":"OG001","title":"Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)"},{"description":"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)\n\n•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:\n\nCohort 1: add CFZ 20 mg/m\\^2 intravenous (IV) on days +1, +2\n\nCohort 2 : add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9\n\nCohort 3: add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m\\^2 IV given on days 42-43 then CFZ 56 mg/m\\^2 IV given on days 49-50, 56-57, then on days 70.","id":"OG002","title":"Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to day 100","title":"Engraftment Failure Transplant Related Mortality","type":"PRIMARY","unitOfMeasure":"participants"}